02511.HK
HighTide Therapeutics Inc
HKSE · Healthcare · Biotechnology · CN
HKD 3.08
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 362.9M | 164.5M | 363.5M | 311.6M | 182.7M |
| SG&A Expense | 137.8M | 59.1M | 81.2M | 136.7M | 43.4M |
| General & Admin Expense | 94.3M | 59.1M | 81.2M | 136.7M | 43.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 500.7M | 223.6M | 444.8M | 448.2M | 226.1M |
| Cost and Expenses | 500.7M | 223.6M | 444.8M | 448.2M | 226.1M |
| Operating Income (EBIT) | (500.7M) | (223.6M) | (444.8M) | (448.2M) | (226.1M) |
| Non-Operating | |||||
| Interest Income | 8.0M | 10.2M | 27.6K | 26.8M | 3.5M |
| Interest Expense | 6.9M | 2.3M | 1.5M | 442.0K | 426.0K |
| Net Interest Income | 4.0M | 7.9M | 27.6K | 26.4M | 3.1M |
| Other Non-Op Income/Expense | (69.7M) | (8.3M) | 63.2M | (491.0M) | 35.9M |
| Non-Operating Income (excl Interest) | (1.0K) | — | — | — | — |
| EBT (Pre-Tax Income) | (570.4M) | (231.9M) | (381.5M) | (939.2M) | (190.2M) |
| Income Tax Expense | 489.0K | 219.0K | 269.0K | 76.0K | 32.0K |
| Bottom Line | |||||
| Net Income | (562.1M) | (245.0M) | (381.8M) | (939.3M) | (190.2M) |
| Earnings from Cont. Ops | (570.4M) | (232.1M) | (381.8M) | (939.3M) | (190.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (562.1M) | (245.0M) | (381.8M) | (939.3M) | (190.2M) |
| Per Share | |||||
| Basic EPS | (HK$1.19) | (HK$0.51) | (HK$0.84) | (HK$3.62) | (HK$0.75) |
| Diluted EPS | (HK$1.19) | (HK$0.51) | (HK$0.84) | (HK$3.62) | (HK$0.75) |
| Revenue Per Share | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 508.7M | 479.7M | 452.1M | 259.7M | 514.8M |
| Diluted Shares Outstanding | 508.7M | 479.7M | 452.1M | 259.7M | 514.8M |
| Profitability Metrics | |||||
| EBITDA | (498.7M) | (222.2M) | (443.7M) | (447.7M) | (225.7M) |
| D&A | 2.0M | 1.4M | 1.0M | 537.0K | 409.0K |
| EBIT | (500.7M) | (223.6M) | (444.8M) | (448.2M) | (226.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026